SCHEMBL15840666

SCHEMBL15840666

COc1ccc(NC(=S)Nc2ccc(S(=O)(=O)Nc3ccc(Cl)c(Cl)c3)cc2)cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.63
HTT P42858 4/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
ALOX15 P16050 1/20 0.63
MAPK1 P28482 1/20 0.63
ALDH1A1 P00352 10/20 0.59
KMT2A Q03164 6/20 0.59
MEN1 O00255 5/20 0.59
MAPT P10636 4/20 0.59
PKM P14618 2/20 0.58
TSHR P16473 2/20 0.58
PPIA P62937 2/20 0.58
NPSR1 Q6W5P4 1/20 0.58
GAA P10253 3/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
THRB P10828 1/20 0.56
HPGD P15428 1/20 0.56
ALOX12 P18054 1/20 0.56
HTR6 P50406 1/20 0.52
CYP1A2 P05177 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15840641 0.88 PPIA (0.74) LMNAHTTSMN1; SMN2ALOX15MAPK1
SCHEMBL15840660 0.87 PPIA (0.62) LMNAHTTSMN1; SMN2ALOX15MAPK1
SCHEMBL14434612 0.85 MAPT (0.78) LMNAHTTSMN1; SMN2ALDH1A1KMT2A
SCHEMBL15840685 0.85 PPIA (0.72) LMNAHTTSMN1; SMN2ALOX15MAPK1
SCHEMBL15840812 0.83 MAPT (0.61) LMNAHTTALDH1A1KMT2AMEN1
SCHEMBL15840508 0.81 ALDH1A1 (0.57) LMNAHTTALDH1A1KMT2AMEN1
SCHEMBL15840806 0.81 ALDH1A1 (0.67) LMNASMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL15840723 0.81 FFAR4 (0.67) LMNAHTTSMN1; SMN2ALOX15MAPK1
SCHEMBL15840714 0.81 HTT (0.67) LMNAHTTSMN1; SMN2ALOX15MAPK1
SCHEMBL15840716 0.81 MAPT (0.72) LMNASMN1; SMN2ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 LMNA 2183/4885HTT 1693/4885SMN1; SMN2 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.